17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression

To assess the role of rare copy number variations in Alzheimer's disease (AD), we conducted a case–control study using whole-exome sequencing data from 522 early-onset cases and 584 controls. The most recurrent rearrangement was a 17q21.31 microduplication, overlapping the CRHR1, MAPT, STH and KANSL1 genes that was found in four cases, including one de novo rearrangement, and was absent in controls. The increased MAPT gene dosage led to a 1.6–1.9-fold expression of the MAPT messenger RNA. Clinical signs, neuroimaging and cerebrospinal fluid biomarker profiles were consistent with an AD diagnosis in MAPT duplication carriers. However, amyloid positon emission tomography (PET) imaging, performed in three patients, was negative. Analysis of an additional case with neuropathological examination confirmed that the MAPT duplication causes a complex tauopathy, including prominent neurofibrillary tangle pathology in the medial temporal lobe without amyloid-β deposits. 17q21.31 duplication is the genetic basis of a novel entity marked by prominent tauopathy, leading to early-onset dementia with an AD clinical phenotype. This entity could account for a proportion of probable AD cases with negative amyloid PET imaging recently identified in large clinical series.

[1]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[2]  J. Rosenfeld,et al.  17q21.31 microduplication patients are characterised by behavioural problems and poor social interaction , 2009, Journal of Medical Genetics.

[3]  D. Campion,et al.  Alzheimer disease: modeling an Aβ-centered biological network , 2016, Molecular Psychiatry.

[4]  Michelle K. Lupton,et al.  Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. , 2012, Human molecular genetics.

[5]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[6]  A. Fagan,et al.  Suspected non-Alzheimer disease pathophysiology — concept and controversy , 2016, Nature Reviews Neurology.

[7]  K. Blennow,et al.  The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? , 2014, Alzheimer's & Dementia.

[8]  R. Redon,et al.  ABCA7 rare variants and Alzheimer disease risk , 2016, Neurology.

[9]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[10]  A. Paetau,et al.  Alzheimer disease PS-1 exon 9 deletion defined , 1999, Nature Medicine.

[11]  R. Redon,et al.  SORL1 rare variants: a major risk factor for familial early-onset Alzheimer’s disease , 2016, Molecular Psychiatry.

[12]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[13]  Petros Drineas,et al.  Familial early-onset dementia with complex neuropathologic phenotype and genomic background , 2016, Neurobiology of Aging.

[14]  D. Campion,et al.  Frontotemporal dementia phenotype associated with MAPT gene duplication. , 2010, Journal of Alzheimer's disease : JAD.

[15]  H. Braak,et al.  PART is part of Alzheimer disease , 2015, Acta Neuropathologica.

[16]  F. Pasquier,et al.  Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites , 2011, Molecular Psychiatry.

[17]  M. Schwartz,et al.  A 17q21.31 microduplication, reciprocal to the newly described 17q21.31 microdeletion, in a girl with severe psychomotor developmental delay and dysmorphic craniofacial features. , 2007, European journal of medical genetics.

[18]  K. Jellinger,et al.  PART, a distinct tauopathy, different from classical sporadic Alzheimer disease , 2015, Acta Neuropathologica.

[19]  M. Tzetis,et al.  Microdeletion and microduplication 17q21.31 plus an additional CNV, in patients with intellectual disability, identified by array-CGH. , 2012, Gene.

[20]  P. Deyn,et al.  Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study , 2015, The Lancet Neurology.

[21]  H. Stefánsson,et al.  Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease , 2015, Nature Genetics.

[22]  R. Tanzi,et al.  Rare autosomal copy number variations in early-onset familial Alzheimer’s disease , 2014, Molecular Psychiatry.

[23]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[24]  A. Montpetit,et al.  Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons , 2015, European Journal of Human Genetics.

[25]  Jason J. Corneveaux,et al.  Analysis of Copy Number Variation in Alzheimer’s Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals , 2012, PloS one.

[26]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[27]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[28]  C. Pantaleoni,et al.  Chromosome 17q21.31 duplication syndrome: Description of a new familiar case and further delineation of the clinical spectrum. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[29]  Johanna Huttenlocher-Moser.  Variant of TREM2 Associated with the Risk of Alzheimer's Disease , 2013 .

[30]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[31]  H. Soininen,et al.  Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early onset Alzheimer's disease family: an Alu core sequence-stimulated recombination? , 2000, European Journal of Human Genetics.

[32]  Monkol Lek,et al.  Patterns of genic intolerance of rare copy number variation in 59,898 human exomes , 2016, Nature Genetics.

[33]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[34]  Michel Goedert,et al.  Tau pathology and neurodegeneration , 2013, The Lancet Neurology.

[35]  Claire Paquet,et al.  A genome-wide study reveals rare CNVs exclusive to extreme phenotypes of Alzheimer disease , 2011, European Journal of Human Genetics.

[36]  G. Abecasis,et al.  Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data. , 2012, American journal of human genetics.

[37]  A. Saykin,et al.  Analysis of copy number variation in Alzheimer's disease: the NIALOAD/ NCRAD Family Study. , 2012, Current Alzheimer research.

[38]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[39]  J. Haines,et al.  Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain gene expression levels , 2014, Alzheimer's Research & Therapy.

[40]  Kali T. Witherspoon,et al.  Refining analyses of copy number variation identifies specific genes associated with developmental delay , 2014, Nature Genetics.

[41]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[42]  Magda Tsolaki,et al.  A NOVEL ALZHEIMER DISEASE LOCUS LOCATED NEAR THE GENE ENCODING TAU PROTEIN , 2015, Molecular Psychiatry.

[43]  Yufeng Shen,et al.  CANOES: detecting rare copy number variants from whole exome sequencing data , 2014, Nucleic acids research.

[44]  A. Morris,et al.  Data quality control in genetic case-control association studies , 2010, Nature Protocols.